HE-S2

• UNSPSC Description:

  HE-S2 is an antibody-drug conjugate triggering a potent antitumor immune response. HE-S2 acts by blocking the PD-1/PD-L1 interaction and activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway. HE-S2 has remarkable antitumor activity[1].

• Target Antigen:

  Drug-Linker Conjugates for ADC; PD-1/PD-L1; Toll-like Receptor (TLR)

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/he-s2.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C[C@H](COC(NC1=CC=C(C[N+](C)(C)CC2=CC=C(CC3=CC=C(N=C(N)N=C4NCCCC)C4=N3)C=C2)C=C1)=O)SSC5=NC=C([N+]([O-])=O)C=C5.[H]C([O-])=O

• Molecular Weight:

  787.95

• References & Citations:

  [1]He L, et al. Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy. J Med Chem. 2021;64(21):15716-15726.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2939851-67-7